Meeting Minutes: Drug Formulary Committee

Date and Time: February 25, 2021; 5:30-9:00 p.m.
Minutes prepared by: Umang Patel and Dave Hoang
Location: Virtual Meeting via Zoom

Attendance

- **Members in attendance:** Stuart Williams, JD.; Tsewang Ngodup, MD.; Tim Cernohous, PharmD. PhD.; Kyle Lehenbauer, MD.; Mary Mescher Benbenek, APRN, PhD.; Kelly Ruby, PharmD.; Monica Brands, RPh.; James Phillips, MD.; Al Heaton, PharmD.; Ramona Powell, PharmD.; Margaret Artz, RPh., PhD.; Michael Sprehe, MD, MPH.
- **Members absent:** Kathryn Lombardo, MD.
- **DHS staff present:** Dave Hoang, PharmD., MBA; Chad Hope, PharmD.; Nathan Chomilo, MD.; DHS Assistant Commissioner Matt Anderson.
- **Others in attendance:** Ariane Casey, PharmD.; Umang Patel, PharmD.

DHS Housekeeping

- DHS Assistant Commissioner Matt Anderson delivered a courtesy message to DFC members regarding DHS Commissioner’s decision to put the implementation of the DFC recommended HIV PDL class on hold.
- DFC welcomed reappointed member Stuart Williams who is the current DFC chair and the public member/consumer representative.
- DFC welcomed two newly appointed members: pharmacist member Tim Cernohous, PharmD. and licensed health care professional member Tsewang Ngodup, MD.
- DFC recognized the contributions of DFC pharmacist member Alan Heaton, PharmD., who is retiring and thanked him for his service to the state of Minnesota.
- Dave Hoang provided an update of changes and upcoming changes to the policies and procedures regarding public comments and participation.

Report of the Chair

- Stuart Williams presided over the meeting.

Approval of Minutes

- Minutes from the October 2020 meetings were reviewed and accepted with no changes
Old Business  – None

New Business

New Specialty Drugs for Continued PA

- The committee discussed Zepzelca and recommended to the department by a unanimous vote that Zepzelca remain on PA with the proposed criteria.

- The committee discussed Phesgo and recommended to the department by a unanimous vote that Phesgo remain on PA with the proposed criteria.

- The committee discussed Fintepla and recommended to the department by a unanimous vote that Fintepla remain on PA with the proposed criteria.

- The committee discussed Dojolvi and recommended to the department by a unanimous vote that Dojolvi remain on PA with the proposed criteria, with the following changes:
  - 3rd bullet of Renewal Criteria: Take the wording "(e.g., GI effects)" away
  - 15th bullet of Initial Approval Criteria: Take out "Patient practicing appropriate dietary measures for their age and specific disorder..." criteria
  - Initial: Make 6 months
  - Renewal: Make 6 months

- The committee discussed Evrysdi and recommended to the department by a unanimous vote that Evrysdi remain on PA with the proposed criteria, with the following changes:
  - Remove 4th bullet in Initial Approval Criteria: "Patient does NOT require invasive ventilation or tracheostomy"
  - Change bullet 3 (sub-bullet 1) from “SMA Type 1 confirmed by 1 of the following...” to “SMA type 1 with symptomatic disease (e.g., impaired motor function and/or delayed motor milestones)"

- The committee discussed Viltepso and recommended to the department by a unanimous vote that Viltepso remain on PA with the proposed criteria, with the following changes:
  - Bullet 9, sub-bullet 1 in Initial Approval Criteria: Remove “Dystrophin Level”
  - Bullet 9, sub-bullet 1 in Renewal Criteria: Remove “Dystrophin Level”
  - Initial criteria be for 6 months
  - Approval criteria be for 6 months

- The committee discussed Inqovi and recommended to the department by a majority vote with one committee member abstaining that Inqovi remain on PA with the proposed criteria, with the following change:
  - Under Initial Approval Criteria, add "Patient is under the care of an Oncologist/Hematologist"
• The committee discussed Blenrep and recommended to the department by a unanimous vote that Blenrep remain on PA with the proposed criteria.

• The committee discussed Enspryng and recommended to the department by a unanimous vote that Enspryng remain on PA with the proposed criteria.

• The committee discussed Monjuvi and recommended to the department by a unanimous vote that Monjuvi remain on PA with the proposed criteria.

• The committee discussed Ongentys and recommended to the department by a majority vote with one committee member abstaining that Ongentys remain on PA with the proposed criteria.

• Due to time-constraint, DFC review of Onureg PA Criteria and Gavreto PA Criteria was postponed until a future meeting

New Drugs for Continued PA

• Due to time-constraint, DFC review of Ortikos and Breztri Aerosphere was postponed until a future meeting.

• The committee discussed Xywav and recommended to the department by a unanimous vote that Xywav remain on PA with the proposed criteria, with the following change:
  o Bullet 10, sub-bullet 1 in Initial Approval Criteria: Flip the order of words “Xyrem” and “sodium oxybate”

• The committee discussed MAT Drugs and Biologicals- SUPPORT Act Compliance and recommended to the department by a unanimous vote, with the following changes:
  o Amend the 3rd bullet to add language that “Member has trial and failure or adverse effect to all Preferred Drugs”
  o Amend the 4th bullet to add language that “Member has trial and failure or adverse effect to all Non-Preferred Drugs”

Preferred Drug List

• The committee discussed the Anticonvulsants therapeutic class and recommended the following to the department by a majority vote, with two members abstaining:
  o LAMOTRIGINE TABLET DOSE PACK to be moved on the PDL as nonpreferred
  o FINTEPLA be added to the PDL as nonpreferred
  o XCOPI TABLET be added to the PDL as nonpreferred
  o XCOPI TITRATION PACK be added to the PDL as nonpreferred
  o RUFINAMIDE SUSPENSION be added to the PDL as nonpreferred
  o SYMPAZAN be added to the PDL as nonpreferred

• The committee discussed the Anticonvulsants, Other therapeutic class and recommended the following to the department by unanimous vote:
- VALTOCO (NASAL) be added to the PDL as preferred
- NAYZILAM (NASAL) remain on the PDL as nonpreferred

- The committee discussed Nayzilam and recommended to the department by a unanimous vote that Nayzilam remain on PA with the proposed criteria.

**Policy Review**

- The committee discussed Nonpreferred Drug Prior Authorization Criteria. After hearing feedback from DFC members, Dave requested that the review of proposed criteria be postponed until a future meeting in order for DHS to have an opportunity to draft additional language to address members’ concern about a potential lack of safeguards for preferred drugs.

- The committee discussed Guidelines for Updating PA Criteria Sheets and recommended by a unanimous vote to postpone this discussion until a future meeting.

**Adjournment**

- The meeting was adjourned at approximately 9:49 p.m. Central Time.